FDA approves Eli Lilly Alzheimer’s drug that slows progress of the disease
The U.S. Food and Drug Administration on Tuesday gave a green light to Eli Lilly’s LLY.N donanemab for patients with early Alzheimer’s. REUTERS WASHINGTON — U.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment. The Food and Drug Administration approved Eli … Read more